Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

The other day I went to see a plastic surgeon who just happens to be Beverly Hills' best-kept secret. You won't find him on ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...

The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Ozempic and its contemporaries are the new craze. But would you believe it when we say that these weight-loss drugs would be ...

Ozempic, a diabetes drug turned weight-loss sensation, generated billions in annual sales, with U.S. pharmacies filling ...

The shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher ...